In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Assistant Professor Francesco Paneni
Speaker
Assistant Professor Francesco Paneni
Francesco Paneni Francesco Paneni

University Heart Center, Zurich (Switzerland)

Specialities : Basic Science , Myocardial Disease, Risk Factors and Prevention

Francesco Paneni was born on October 20, 1981 in Rome, Italy. Dr. Paneni obtained his MD degree in 2006 and then started his clinical training in Cardiology at the University of Rome “Sapienza”. In 2005 he spent 4 months at Mount Sinai Medical Centre in New York, where he obtained a first-level master in cardiac CT and MRI. In July 2011, he fulfilled all the requirements for Board Certification in Cardiology. In 2014, he obtained the Ph.D. in Experimental Medicine at the University of Rome “Sapienza”. From 2011 to 2013 he worked as Research Associate in the Cardiovascular Research team of Prof. Luscher at the University of Zurich, Switzerland. From 2014 to 2017, Dr. Paneni has worked as Research Associate at the Unit of Cardiology and Center for Molecular Medicine, Karolinska Institute. On January 2017, he was appointed Assistant Professor and Research Group Leader at the University of Zurich, in the Centre for Molecular Cardiology.

15 presentations from this speaker

Diabetes – Implementing the recent breakthroughs.

Event : ESC Congress 2019

  • Session : The European Heart Journal’s advances from prevention to intervention: the year in Cardiology
  • Speaker : F Paneni (Schlieren,CH)
  • Joint with the European Heart Journal

Prevention in 2018 - Diabetes.

Event : ESC Congress 2018

  • Session : The European Heart Journal’s advances from prevention to intervention: the year in Cardiology
  • Speaker : F Paneni (Schlieren,CH)
  • Joint with the European Heart Journal

Methyltransferase Set7 drives vascular inflammation and endothelial dysfunction in obesity

Event : ESC Congress 2016

  • Session : The immune system in cardiovascular disease
  • Speaker : F Paneni (Schlieren,CH)

Mitochondrial oxidative stress and vascular dysfunction in diabetes

Event : Frontiers in CardioVascular Biology 2016

  • Session : Sciences within European Young Researcher Community
  • Speaker : F Paneni (Schlieren,CH)

Prolyl-isomerase-1 (Pin1) causes endothelial dysfunction and vascular inflammation in diabetes: a study in mice and humans

Event : ESC Congress 2014

  • Session : Young Investigators Awards Session Basic Science
  • Speaker : F Paneni (Schlieren,CH)

Transcription factors in age-related vascular dysfunction.

Event : ESC Congress 2014

  • Session : Transcriptional regulation: deciphering the network
  • Speaker : F Paneni (Schlieren,CH)

Prolyl-isomerase-1 (pin1) mediates hyperglycemia-induced oxidative stress, endothelial function and vascular inflammation: insights in patients with type 2 diabetes

Event : ESC Congress 2013

  • Session : Mechanisms involved in ischaemia, metabolism and stress adaptation
  • Speaker : F Paneni (Schlieren,CH)

The lifespan determinant p66shc drives obesity-induced oxidative stress, mitochondrial dysfunction and vascular inflammation

Event : ESC Congress 2013

  • Session : Rapid Fire - Protein changes: metabolism, injury and protection
  • Speaker : F Paneni (Schlieren,CH)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are